News
Zurzuvae (zuranolone) can cause side effects that range from mild to serious. More common side effects include dizziness and diarrhea. If side effects from Zurzuvae become difficult to tolerate ...
Sage Therapeutics Inc (SAGE) reports significant growth in ZURZUVAE prescriptions and collaboration revenue, alongside a substantial reduction in R&D expenses.
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to ...
CEO Barry Greene highlighted a strong start to 2025 with significant milestones for ZURZUVAE, the first oral treatment approved for postpartum depression (PPD). Over 3,000 prescriptions were ...
Our Chief Operating Officer, Chris Benecchi, will provide an update on the ongoing commercialization of ZURZUVAE and key financial results from the first quarter 2025. Our Chief Scientific Officer ...
Achieved $13.8 million in ZURZUVAE ® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth ...
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...
The failed postpartum depression bill spurs Alabama Medicaid to ease drug approval for new mothers. MONTGOMERY, Ala. — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results